Research Article

Functional MAOB Gene Intron 13 Polymorphism Predicts Dyskinesia in Parkinson’s Disease

Table 1

Cox proportional hazard ratios estimating the risk for motor complications with respect to genotypes in functional polymorphisms associated with lower enzyme/transporter activitya.

Wearing-offLevodopa-induced dyskinesiaAny motor complication
HR (95% CI)bAdjusted HR (95% CI)b,cHR (95% CI)bAdjusted HR (95% CI)b,cHR (95% CI)b,c

DDCCC/CT (rs921451)0.569 (0.218–1.488)0.2500.633 (0.240–1.668)0.3550.699 (0.218–2.244)0.5480.801 (0.237–2.705)0.7210.514 (0.196–1.350)0.177
MAOBCC/(C)/CT (rs1799836)0.566 (0.242–1.322)0.1890.197 (0.563–1.347)0.1970.264 (0.089–0.787)0.0120.142 (0.039–0.520)0.0030.554 (0.235–1.304)0.176
COMTAA/AG (rs4680)1.216 (0.410–3.607)0.7251.277 (0.430–3.789)0.6605.526 (0.725–42.095)0.0995.298 (0.677–41.484)0.1121.280 (0.432–3.795)0.656
DAT≤9/≤10 (VNTR)0.869 (0.370–2.039)0.7461.081 (0.452–2.582)0.8610.943 (0.335–2.655)0.9121.108 (0.372–3.295)0.8540.994 (0.422–2.338)0.988

HR: hazard ratio; 95% CI: 95% confidence interval. aPatients were grouped into low/intermediate enzyme/transporter activity (DDCCC/CT (n = 23); MAOBCC/(C)/CT (n = 16); COMTAA/AG (n = 23); DAT≤9/≤10 (n = 13)) and high enzyme/transporter activity (DDCTT (n = 7); MAOBTT/(T) (n = 14); COMTGG (n = 7); DAT10/10 (n = 17)). Refer to Supplementary Table S1 for details. bAn HR < 1 indicates smaller risk for motor complications with genotypes resulting in low/intermediate enzyme/transporter activity (DDCCC/CT rs921451 genotype; MAOBCC/(C)/CT rs1799836 genotype; COMTAA/AG rs4680 genotype; DAT≤9/≤10 V NTR genotype). cAdjustment of HR for relevant covariates was performed by using multivariate Cox proportional hazard models using a stepwise selection process retaining as final variables disease duration at baseline for the prediction of wearing-off, gender, disease duration at baseline, and MAOB-I therapy for levodopa-induced dyskinesia and no variables for any motor complication (no adjustment needed).